Fig. 2: Protective efficacy of LNP-mRNA-H5HA vaccine against homologous or heterologous virus challenge. | npj Vaccines

Fig. 2: Protective efficacy of LNP-mRNA-H5HA vaccine against homologous or heterologous virus challenge.

From: An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection

Fig. 2

a Timeline of the virus challenge study. Groups of BALB/c mice (7-wk-old females; N = 5/group) were intramuscularly (i.m.) mock-vaccinated or vaccinated with 1 or 10 μg of DS8390 by using a prime & boost regimen. Pre-challenge sera collected 2 wks post-boost were analyzed in an ELISA (Supplementary Fig. 2) and a neutralization assay (Supplementary Table 1). At 3 wks post-boost immunization, the animals were intranasally (i.n.) challenged with 10 MLD50 of homologous A/chicken/Ghana/AVL-76321VIR7050-39/2021 (ch/Ghana; 6.1 × 102pfu/animal) virus (b, c) or heterologous A/India/SARI-4571/2021 (India/S4571; 3.2 × 102pfu/animal) virus (d, e). Survival rate (b, d) and body weight change (c, e) were monitored for 14 days (% compared to Day 0; mean + SD).

Back to article page